The IASLC lung cancer staging project: Proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 8, 2016, Pages 1204-1223

  Travis, William D ^a   Asamura, Hisao ^b   Bankier, Alexander A ^c   Beasley, Mary Beth ^d   Detterbeck, Frank ^e,v   Flieder, Douglas B ^f   Goo, Jin Mo ^g   MacMahon, Heber ^h   Naidich, David ⁱ   Nicholson, Andrew G ^j   Powell, Charles A ^d   Prokop, Mathias ^k   Rami Porta, Ramón ^l,m,q   Rusch, Valerie ^a   Van Schil, Paul ⁿ   Yatabe, Yasushi ^o   Goldstraw, Peter ^p   Ball, David ^r   Beer, David ^s   Beyruti, Ricardo ^t   Bolejack, Vanessa ^u   Chansky, Kari ^u   Crowley, John ^u   Eberhardt, Wilfried Ernst Erich ^w   Edwards, John ^x   Galateau Sallé, Françoise ^y   Giroux, Dorothy ^u   Gleeson, Fergus ^z   Groome, Patti ^aa   Huang, James ^a   Kennedy, Catherine ^ab   Kim, Jhingook ^ac   Kim, Young Tae ^g   Kingsbury, Laura ^u   Kondo, Haruhiko ^ad   Krasnik, Mark ^ae   Kubota, Kaoru ^af   Lerut, Antoon ^ag   Lyons, Gustavo ^ah   Marino, Mirella ^ai   Marom, Edith M ^aj   Van Meerbeeck, Jan ⁿ   Mitchell, Alan ^u   Nakano, Takashi ^ak   Nowak, Anna ^al   Peake, Michael ^am   Rice, Thomas ^an   Rosenzweig, Kenneth ^ao   Ruffini, Enrico ^ap   Saijo, Nagahiro ^aq   Sculier, Jean Paul ^ar   Shemanski, Lynn ^u   Stratton, Kelly ^u   Suzuki, Kenji ^as   Tachimori, Yuji ^at   Thomas, Charles F ^au   Tsao, Ming S ^av   Turrisi, Andrew ^aw   Vansteenkiste, Johan ^ag   Watanabe, Hirokazu ^ax   Wu, Yi Long ^ay   Baas, Paul ^az   Erasmus, Jeremy ^aj   Hasegawa, Seiki ^ak   Inai, Kouki ^ba   Kernstine, Kemp ^bb   Kindler, Hedy ^bc   Krug, Lee ^a   Nackaerts, Kristiaan ^ag   Pass, Harvey ^bd   Rice, David ^aj   Falkson, Conrad ^be   Filosso, Pier Luigi ^ap   Giaccone, Giuseppe ^bf   Kondo, Kazuya ^bg   Lucchi, Marco ^bh   Okumura, Meinoshin ^bi   Blackstone, Eugene ^an   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KEIO UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g Seoul National University   (South Korea)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^k RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^l Hospital Universitario Mutua Terrassa   (Spain)

^m INSTITUTO DE SALUD CARLOS III   (Spain)

ⁿ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

^p ROYAL BROMPTON HOSPITAL   (United Kingdom)

^q HOSPITAL MÚTUA DE TERRASSA   (Spain)

^r PETER MACCALLUM CANCER CENTRE   (Australia)

^s UNIVERSITY OF MICHIGAN   (United States)

^t UNIVERSITY OF SÃO PAULO   (Brazil)

^u Fred Hutchinson Cancer Research Center   (United States)

^v YALE UNIVERSITY   (United States)

^w UNIVERSITY HOSPITAL ESSEN   (Germany)

^x NORTHERN GENERAL HOSPITAL   (United Kingdom)

^y CAEN UNIVERSITY HOSPITAL   (France)

^z CHURCHILL HOSPITAL   (United Kingdom)

^aa QUEEN S UNIVERSITY   (Canada)

^ab UNIVERSITY OF SYDNEY   (Australia)

^ac Samsung Medical Center   (South Korea)

^ad KYORIN UNIVERSITY   (Japan)

^ae GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^af NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^ag UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ah HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^ai REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^aj UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ak HYOGO COLLEGE OF MEDICINE   (Japan)

^al UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^am GLENFIELD HOSPITAL   (United Kingdom)

^an LERNER RESEARCH INSTITUTE   (United States)

^ao MOUNT SINAI HOSPITAL   (United States)

^ap UNIVERSITY OF TURIN   (Italy)

^aq NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^ar JULES BORDET INSTITUTE   (Belgium)

^as JUNTENDO UNIVERSITY   (Japan)

^at NATIONAL CANCER CENTER   (Japan)

^au MAYO CLINIC   (United States)

^av PRINCESS MARGARET HOSPITAL   (Canada)

^aw SINAI GRACE HOSPITAL   (United States)

^ax NATIONAL CANCER CENTER HOSPITAL   (Japan)

^ay GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^az NETHERLANDS CANCER INSTITUTE   (Netherlands)

^ba HIROSHIMA UNIVERSITY   (Japan)

^bb CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^bc UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^bd NEW YORK UNIVERSITY   (United States)

^be QUEEN S UNIVERSITY   (Canada)

^bf GEORGETOWN UNIVERSITY   (United States)

^bg UNIVERSITY OF TOKUSHIMA   (Japan)

^bh UNIVERSITY OF PISA   (Italy)

^bi OSAKA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADENOCARCINOMA IN SITU; BOWEN DISEASE; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; HUMAN; INVASIVE PROCEDURE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NODULE; LUNG VOLUME; MINIMALLY INVASIVE ADENOCARCINOMA; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SOLID TUMOR; TUMOR VOLUME; CLASSIFICATION; DIAGNOSTIC IMAGING; LUNG TUMOR; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADENOCARCINOMA IN SITU; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84982156931     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.03.025     Document Type: Review

References (104)

1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
2. Travis WD, Brambilla E, Noguchi M, et al. The New IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6: 244-285.
3. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015.
4. Wittekind C, Compton CC, Brierley J, Sobin LH, eds. TNM Supplement: A Commentary on Uniform Use. 4th ed. Oxford, United Kingdom: Wiley-Blackwell; 2012.
5. Wittekind C, Greene FL, Henson DE, Hutter RVP, Sobin LH, eds. TNM Supplement: A Commentary on Uniform Use. 3rd ed. New York: Wiley-Liss; 2003.
6. Wittekind C, Henson DE, Hutter RVP, Sobin L, eds. TNM Supplement. A Commentary on Uniform Use. 2nd ed. New York: Wiley-Liss; 2001.
7. Lim HJ, Ahn S, Lee KS, et al. Persistent pure groundglass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications. Chest. 2013;144:1291-1299.
8. Yamada N, Kusumoto M, Maeshima A, Suzuki K, Matsuno Y. Correlation of the solid part on high-resolution computed tomography with pathological scar in small lung adenocarcinomas. Jpn J Clin Oncol. 2007;37:913-917.
9. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology. 2013;266: 304-317.
10. Infante M, Lutman RF, Imparato S, et al. Differential diagnosis and management of focal ground-glass opacities. Eur Respir J. 2009;33:821-827.
11. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143: e93S-e120S.
12. Park CM, Goo JM, Lee HJ, Lee CH, Chun EJ, Im JG. Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up. Radiographics. 2007;27:391-408.
13. Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an underrecognised spectrum of disease. Thorax. 2007;62: 248-252.
14. Gu B, Burt BM, Merritt RE, et al. A dominant adenocarcinoma with multifocal ground glass lesions does not behave as advanced disease. Ann Thorac Surg. 2013;96:411-418.
15. Shrager JB. Approach to the patient with multiple lung nodules. Thorac Surg Clin. 2013;23:257-266.
16. Tsutsui S, Ashizawa K, Minami K, et al. Multiple focal pure ground-glass opacities on high-resolution CT images: clinical significance in patients with lung cancer. AJR Am J Roentgenol. 2010;195:W131-W138.
17. Kadota K, Villena-Vargas J, Yoshizawa A, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol. 2014;38:448-460.
18. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653-664.
19. Nakagiri T, Sawabata N, Morii E, et al. Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma. Gen Thorac Cardiovasc Surg. 2014;62:671-677.
20. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg. 2014;98: 453-458.
21. Warth A, Muley T, Meister M, et al. The novel histologic IASLC/ATS/ERS classification system of invasive pulmonary adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30: 1438-1446.
22. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8:52-61.
23. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients-based on a hospital study in China. Eur J Surg Oncol. 2013;39:1262-1268.
24. Takahashi M, Shigematsu Y, Ohta M, Tokumasu H, Matsukura T, Hirai T. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters. J Thorac Cardiovasc Surg. 2014;147: 54-59.
25. Yoshida J, Ishii G, Yokose T, et al. Possible delayed cutend recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients. J Thorac Oncol. 2010;5:546-550.
26. Kadota K, Nitadori JI, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences following limited resection for small stage I lung adenocarcinomas. J Thorac Oncol. 2015;10: 806-814.
27. Warth A, Muley T, Kossakowski CA, et al. Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol. 2015;39:793-801.
28. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371-376.
29. Xu L, Tavora F, Battafarano R, Burke A. Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society. Am J Surg Pathol. 2012;36:273-282.
30. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol. 2009;33:1752-1764.
31. Ito M, Miyata Y, Kushitani K, et al. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. Lung Cancer. 2014;85:270-275.
32. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: American Joint Committee on Cancer; 2010.
33. Sobin L, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009.
34. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990-1003.
35. de Groot PM, Carter BW. Betancourt Cuellar SL, Erasmus JJ. Staging of Lung Cancer. Clin Chest Med. 2015;36: 179-196.
36. Zhang J, Gold KA, Lin HY, et al. Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): an analysis of the Surveillance, Epidemiology, and End Results (SEER) registry. J Thorac Oncol. 2015;10:682-690.
37. Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol. 2012;7: 1479-1484.
38. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593-602.
39. Rusch VW, Appleman HD, Blackstone E, et al., eds. AJCC Cancer Staging Manual. Chicago, IL: Springer; 2009: 253-270.
40. Goldstraw P, ed. IASLC Staging Manual in Thoracic Oncology. Orange Park, FL: Editorial Rx Press; 2009.
41. Tsutani Y, Miyata Y, Mimae T, et al. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2013;146:580-585.
42. Maeyashiki T, Suzuki K, Hattori A, Matsunaga T, Takamochi K, Oh S. The size of consolidation on thinsection computed tomography is a better predictor of survival than the maximum tumour dimension in resectable lung cancer. Eur J Cardiothorac Surg. 2013;43:915-918.
43. Tsutani Y, Miyata Y, Yamanaka T, et al. Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using highresolution computed tomography findings. J Thorac Cardiovasc Surg. 2013;146:17-23.
44. Tsutani Y, Miyata Y, Nakayama H, et al. Solid tumor size on high-resolution computed tomography and maximum standardized uptake on positron emission tomography for new clinical T descriptors with T1 lung adenocarcinoma. Ann Oncol. 2013;24:2376-2381.
45. Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study. J Thorac Cardiovasc Surg. 2012;143:607-612.
46. Murakawa T, Konoeda C, Ito T, et al. The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma. Eur J Cardiothorac Surg. 2013;43:925-932.
47. Hwang EJ, Park CM, Ryu Y, et al. Pulmonary adenocarcinomas appearing as part-solid ground-glass nodules: is measuring solid component size a better prognostic indicator? Eur Radiol. 2015;25:558-567.
48. Burt BM, Leung AN, Yanagawa M, et al. Diameter of solid tumor component alone should be used to establish T stage in lung adenocarcinoma. Ann Surg Oncol. 2015;22(suppl 3):1318-1323.
49. Cohen JG, Reymond E, Lederlin M, et al. Differentiating pre-and minimally invasive from invasive adenocarcinoma using CT-features in persistent pulmonary partsolid nodules in Caucasian patients. Eur J Radiol. 2015;84:738-744.
50. Zhang Y, Qiang JW, Ye JD, Ye XD, Zhang J. High resolution CT in differentiating minimally invasive component in early lung adenocarcinoma. Lung Cancer. 2014;84:236-941.
51. Zhang H, Duan J, Li ZJ, et al. Analysis on minimally invasive diagnosis and treatment of 49 cases with solitary nodular ground-glass opacity. J Thorac Dis. 2014;6:1452-1457.
52. Lee HY, Choi YL, Lee KS, et al. Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging, and management. AJR Am J Roentgenol. 2014;202: W224-W233.
53. Lee HY, Lee KS. Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. J Thorac Imaging. 2011;26:106-118.
54. Isaka T, Yokose T, Ito H, et al. Comparison between CT tumor size and pathological tumor size in frozen section examinations of lung adenocarcinoma. Lung Cancer. 2014;85:40-46.
55. Lee SM, Park CM, Goo JM, Lee HJ, Wi JY, Kang CH. Invasive pulmonary adenocarcinomas versus preinvasive lesions appearing as ground-glass nodules: differentiation by using CT features. Radiology. 2013;268:265-273.
56. Nakata M, Sawada S, Saeki H, et al. Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography. Ann Thorac Surg. 2003;75:1601-1605.
57. Lee HJ, Goo JM, Lee CH, Yoo CG, Kim YT, Im JG. Nodular ground-glass opacities on thin-section CT: size change during follow-up and pathological results. Korean J Radiol. 2007;8:22-31.
58. Son JY, Lee HY, Lee KS, et al. Quantitative CTanalysis of pulmonary ground-glass opacity nodules for the distinction of invasive adenocarcinoma from preinvasive or minimally invasive adenocarcinoma. PLoS One. 2014;9:e104066.
59. Mimae T, Miyata Y, Tsutani Y, et al. What are the radiologic findings predictive of indolent lung adenocarcinoma? Jpn J Clin Oncol. 2015;45:367-372.
60. Nakamura H, Saji H, Ogata A, Saijo T, Okada S, Kato H. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection. Lung Cancer. 2004;44:61-68.
61. Kitami A, Sano F, Hayashi S, et al. Correlation between histological invasiveness and the computed tomography value in pure ground-glass nodules. Surg Today. 2016;46:593-598.
62. Oda S, Awai K, Liu D, et al. Ground-glass opacities on thin-section helical CT: differentiation between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. AJR Am J Roentgenol. 2008;190: 1363-1368.
63. Lee HJ, Goo JM, Lee CH, et al. Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance. Eur Radiol. 2009;19:552-560.
64. Miyata N, Endo M, Nakajima T, et al. High-resolution computed tomography findings of early mucinous adenocarcinomas and their pathologic characteristics in 22 surgically resected cases. Eur J Radiol. 2015;84: 993-997.
65. Lee KH, Goo JM, Park SJ, et al. Correlation between the size of the solid component on thin-section ct and the invasive component on pathology in small lung adenocarcinomas manifesting as ground-glass nodules. J Thorac Oncol. 2014;9:74-82.
66. Lee SM, Goo JM, Lee KH, Chung DH, Koh J, Park CM. CT findings of minimally invasive adenocarcinoma (MIA) of the lung and comparison of solid portion measurement methods at CT in 52 patients. Eur Radiol. 2015;25: 2318-2325.
67. Manos D, Seely JM, Taylor J, Borgaonkar J, Roberts HC, Mayo JR. The Lung Reporting and Data System (LURADS): a proposal for computed tomography screening. Can Assoc Radiol J. 2014;65:121-134.
68. Pinsky PF, Gierada DS, Black W, et al. Performance of lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015;162: 485-491.
69. Watanabe H, Saito H, Yokose T, et al. Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma. Ann Thorac Surg. 2015;99:975-982.
70. Hsu PK, Huang HC, Hsieh CC, et al. Effect of formalin fixation on tumor size determination in stage I nonsmall cell lung cancer. Ann Thorac Surg. 2007;84: 1825-1829.
71. Borczuk AC. Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Mod Pathol. 2012;25(suppl 1):S1-S10.
72. Lampen-Sachar K, Zhao B, Zheng J, et al. Correlation between tumor measurement on computed tomography and resected specimen size in lung adenocarcinomas. Lung Cancer. 2012;75:332-335.
73. Xu X, Chung JH, Jheon S, et al. The accuracy of frozen section diagnosis of pulmonary nodules: evaluation of inflation method during intraoperative pathology consultation with cryosection. J Thorac Oncol. 2010;5: 39-44.
74. Thunnissen FB, Beasley MB, Borczuk A, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol. 2012;25: 1574-1583.
75. Warth A, Stenzinger A, von Brunneck AC, et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification. Eur Respir J. 2012;40: 1221-1227.
76. Warth A, Cortis J, Fink L, et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch. 2012;461:185-193.
77. Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7:825-832.
78. Hellmann MD, Chaft JE, William Jr WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-e50.
79. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007:132.
80. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005;237:395-400.
81. Nair A, Baldwin DR, Field JK, Hansell DM, Devaraj A. Measurement methods and algorithms for the management of solid nodules. J Thorac Imaging. 2012;27: 230-239.
82. de Hoop B, Gietema H, van de Vorst S, Murphy K, van Klaveren RJ, Prokop M. Pulmonary ground-glass nodules: increase in mass as an early indicator of growth. Radiology. 2010;255:199-206.
83. Bogot NR, Kazerooni EA, Kelly AM, Quint LE, Desjardins B, Nan B. Interobserver and intraobserver variability in the assessment of pulmonary nodule size on CT using film and computer display methods. Acad Radiol. 2005;12:948-956.
84. Reeves AP, Biancardi AM, Apanasovich TV, et al. The Lung Image Database Consortium (LIDC): a comparison of different size metrics for pulmonary nodule measurements. Acad Radiol. 2007;14:1475-1485.
85. Revel MP, Bissery A, Bienvenu M, Aycard L, Lefort C, Frija G. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? Radiology. 2004;231:453-458.
86. Lillington GA, Caskey CI. Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med. 1993;14:111-119.
87. Gietema HA, Wang Y, Xu D, et al. Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. Radiology. 2006;241:251-257.
88. Goodman LR, Gulsun M, Washington L, Nagy PG, Piacsek KL. Inherent variability of CT lung nodule measurements in vivo using semiautomated volumetric measurements. AJR Am J Roentgenol. 2006;186: 989-994.
89. Marchiano A, Calabro E, Civelli E, et al. Pulmonary nodules: volume repeatability at multidetector CT lung cancer screening. Radiology. 2009;251:919-925.
90. Wormanns D, Kohl G, Klotz E, et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility. Eur Radiol. 2004;14:86-92.
91. Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B, Henschke CI. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology. 2000;217:251-256.
92. Kim H, Park CM, Woo S, et al. Pure and part-solid pulmonary ground-glass nodules: measurement variability of volume and mass in nodules with a solid portion less than or equal to 5 mm. Radiology. 2013;269:585-593.
93. Kim H, Park CM, Lee SM, Lee HJ, Goo JM. A comparison of two commercial volumetry software programs in the analysis of pulmonary ground-glass nodules: segmentation capability and measurement accuracy. Korean J Radiol. 2013;14:683-691.
94. Petrou M, Quint LE, Nan B, Baker LH. Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology. AJR Am J Roentgenol. 2007;188:306-312.
95. Goo JM, Tongdee T, Tongdee R, Yeo K, Hildebolt CF, Bae KT. Volumetric measurement of synthetic lung nodules with multi-detector row CT: effect of various image reconstruction parameters and segmentation thresholds on measurement accuracy. Radiology. 2005;235:850-856.
96. Ravenel JG, Leue WM, Nietert PJ, Miller JV, Taylor KK, Silvestri GA. Pulmonary nodule volume: effects of reconstruction parameters on automated measurements-a phantom study. Radiology. 2008;247:400-408.
97. Wang Y, de Bock GH, van Klaveren RJ, et al. Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability. Eur Radiol. 2010;20:1180-1187.
98. Yoshida J, Ishii G, Hishida T, et al. Limited resection trial for pulmonary ground-glass opacity nodules: case selection based on high-resolution computed tomographyinterim results. Jpn J Clin Oncol. 2015;45:677-681.
99. Shen WC, Liu JC, Shieh SH, et al. Density features of screened lung tumors in low-dose computed tomography. Acad Radiol. 2014;21:41-51.
100. Sakao Y, Kuroda H, Mun M, et al. Prognostic significance of tumor size of small lung adenocarcinomas evaluated with mediastinal window settings on computed tomography. PLoS One. 2014;9:e110305.
101. Ko JP, Rusinek H, Jacobs EL, et al. Small pulmonary nodules: volume measurement at chest CT-phantom study. Radiology. 2003;228:864-870.
102. Willemink MJ, Leiner T, Budde RP, et al. Systematic error in lung nodule volumetry: effect of iterative reconstruction versus filtered back projection at different CT parameters. AJR Am J Roentgenol. 2012;199:1241-1246.
103. Petkovska I, Brown MS, Goldin JG, et al. The effect of lung volume on nodule size on CT. Acad Radiol. 2007;14:476-485.
104. Hayes DF, Allred C, Anderson BO, et al. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:345-377.